TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report published on Wednesday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Performance

Shares of NASDAQ TXMD opened at $1.76 on Wednesday. TherapeuticsMD has a one year low of $1.43 and a one year high of $3.86. The business has a 50-day moving average price of $1.74 and a two-hundred day moving average price of $2.00.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter. The company had revenue of $0.23 million for the quarter.

Hedge Funds Weigh In On TherapeuticsMD

A number of hedge funds have recently modified their holdings of TXMD. Prosperity Consulting Group LLC purchased a new position in TherapeuticsMD in the first quarter valued at about $56,000. Clearline Capital LP raised its stake in shares of TherapeuticsMD by 18.9% during the 2nd quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock worth $1,025,000 after purchasing an additional 101,282 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of TherapeuticsMD during the 4th quarter valued at about $612,000. 30.74% of the stock is owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.